Navigation Links
Immunotech Laboratories (IMMB) Patented "IPF" Technology A Serious Contender In The Race For HIV & Cancer Cures
Date:2/4/2013

PASADENA, Calif., Feb. 4, 2013 /PRNewswire/ -- CSNNewswire/Immunotech Laboratories, Inc. (PINKSHEETS:IMMB)

Company Director Mr. Bo. Linton of Immunotech Laboratories, Inc, a  Pasadena California based publicly traded company with patented "IPF" Technology  today stated Immunotech's technology  is now considered a major contender in the race for HIV & Cancer cures.  Recent information provided by the company for clinical testing results in both the HIV and Cancer sectors for terminal (Salvage) patients showed the use of the company's patented "IPF" vaccine treatments significantly reduced the number of infected cells while leaving the non infected cells in tact, and almost immediately started the regeneration of the body's natural immune system.

Mr. Linton further commented the company recently received an initial inquiry for a significant order of the company's patented HIV vaccine by an International associate for use as an "Experimental Drug".  If confirmed the initial order would be in excess of several Million Dollars. This would expand the company's operations from Research & Development to a Bio-Pharma manufacturing company.  In Africa, where approved experimental treatments are permitted, there are approximately 30 Million HIV/AIDS patients alone.

About Immunotech Laboratories

Immunotech Laboratories is a drug development company committed to the commercialization of its proprietary proteins for the treatment of debilitating infectious diseases such as HIV, Cancer, Hepatitis and AIDS. Immunotech is committed to creating drugs for the better health of mankind.  Please visit Immunotechlab.com for information regarding the companies patented treatments, valuations and goals.

Safe Harbor Statement: This news release contains forward-looking statements that involve risks and uncertainties associated with financial projections, budgets, milestone timelines, clinical development, regulatory approvals, and other risks described by Immunotech Laboratories, Inc. from time to time in its periodic reports filed with the SEC. IPF is not approved by the US Food and Drug Administration or by any comparable regulatory agencies elsewhere in the world. While Immunotech Laboratories believes that the forward-looking statements and underlying assumptions contained therein are reasonable, any of the assumptions could be inaccurate, including, but not limited to, the ability of Immunotech Laboratories to establish the efficacy of IPF in the treatment of any disease or health condition, the development of studies and strategies leading to commercialization of IPF in the United States, the obtaining of funding required to carry out the development plan, the completion of studies and tests on time or at all, and the successful outcome of such studies or tests. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, Immunotech Laboratories or any other person that the objectives and plans of Immunotech Laboratories will be achieved should not regard the forward-looking statements as a representation.

Immunotech Contact
ir@immunotechlab.com

Investor Relations:
The Nabors Group: 713-875-9200
E-mail: naborsgroup@yahoo.com
www.facebook.com/Naborsgroup


'/>"/>
SOURCE Immunotech Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Immunotech Laboratories Announces LOI With International Bio-Tech Partner For USA Clinical Trials Funding Of Patented HIV Medicines
2. Nelson Laboratories to Host Free Educational Device Testing Classes at 2013 MD&M West Show
3. Charleston Laboratories, Inc. Begins Enrollment for CL-108 Phase 3 Clinical Trial
4. Charleston Laboratories, Inc. beginnt mit klinischer Phase 3-Studie für CL-108
5. Heraeus Named "Supplier of the Year" by National Association of Dental Laboratories
6. New Jensen Dental White Paper Reveals How Dental Laboratories Can Increase Productivity, Profitability with a Multi-Function Pressing Furnace
7. AAIPharma Announces Promotion Of Dean Shirazi To EVP Of Analytical Laboratories
8. IDEXX Laboratories Announces Entry Into Consent Agreement with FTC Bureau of Competition Staff
9. Abuse Deterrent Medicines Developer Pisgah Laboratories, Inc. Wins Top 5 Technologies Award from CLAAD
10. Abuse-Deterrent Medication Developer, Pisgah Laboratories, Achieves Top 5 Technologies Ranking
11. Nelson Laboratories to Present Cleaning Validation Guidelines at BIOMEDevice San Jose
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... , April 19, 2017  SARES•REGIS Group ... it is developing at Conejo Spectrum Business Park ... to Atara Biotherapeutics, Inc. , a biopharmaceutical ... and life-threatening diseases that have been underserved by ... T-cell therapies for cancer, autoimmune and infectious disease. ...
(Date:4/18/2017)... , April 18, 2017 Viverae ® , ... announce the integration of IBM ® Watson Campaign ... deliver targeted communications for a personalized experience. Through digital ... on their health in real time. The enhanced experience ... most to members, wherever they are in their journey ...
(Date:4/18/2017)... and BLOOMINGTON, Minn. ... (NASDAQ: IMMY ) ("Imprimis"), an ophthalmology-focused ... Lens ("Precision Lens"), today announced the signing of ... agreement, Precision Lens will deploy a dedicated sales ... geographies in the U.S., primarily focused in 13 ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... ... to announce the ATA 2017 President’s Awards recipients, comprised of organizations and ... healthcare delivery. , The ATA 2017 President’s Awards recognize individuals and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility ... in pelvic conditions and has helped many women become pregnant upon treating their ... of office-based and simple outpatient evaluations. We can provide the necessary information ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... an agile ecosystem and domain expertise for sponsors and CROs to speed ... trial supply management (RTSM) software platform. Bioclinica AGILE RTSM provides ...
(Date:4/25/2017)... , ... April 25, 2017 ... ... in Newport Beach, California, committed to raising awareness for Duchenne muscular dystrophy, ... from its randomized CAP-1002 (cardiosphere-derived cells) Phase I/II HOPE clinical trial in ...
(Date:4/25/2017)... ... 2017 , ... Lake Park Dental is now accepting new patients with crooked ... FL. With the help of this highly-effective, yet convenient system, patients can straighten their ... and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth ...
Breaking Medicine News(10 mins):